Not Tagged
in8bio
['aml,(-streamline),(-seamless),(-kamloops),(-latamleaders),(-dreamlike)', 'in8bio']
inb-100 ongoing phase 1 trial data: 100% durable complete response progression-free 2.5+ years duration of response manageable safety profile with no dose-limiting toxicities
click for full details: #ash22
#gdtcell
#celltherapy 